Видео ютуба по тегу Dr. Bröckelmann

Strategies used to enhance checkpoint inhibition in Hodgkin lymphoma
Strategies used to enhance checkpoint inhibition in Hodgkin lymphoma
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Dr. W. Bröckelmann
Dr. W. Bröckelmann
The importance of individualizing treatment approaches in HL to improve patient outcomes
The importance of individualizing treatment approaches in HL to improve patient outcomes
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Recent clinical developments in the treatment landscape for older patients with HL
Recent clinical developments in the treatment landscape for older patients with HL
Carl Brockelmann
Carl Brockelmann
Novel approaches in HL
Novel approaches in HL
Updates from the Phase II AERN trial: nivolumab and radiotherapy for the treatment of R/R HL
Updates from the Phase II AERN trial: nivolumab and radiotherapy for the treatment of R/R HL
Need for innovative treatments for HL: Creating a benchmark
Need for innovative treatments for HL: Creating a benchmark
Very late relapse in Hodgkins lymphoma
Very late relapse in Hodgkins lymphoma
Hämatologie im Wandel Interview mit Dr. med. Nicola Gökbuget und Prof. Dr. med. Michael Hallek
Hämatologie im Wandel Interview mit Dr. med. Nicola Gökbuget und Prof. Dr. med. Michael Hallek
David Bröckelmann bei Kurt Aeschbacher (Teil 2 von 2)
David Bröckelmann bei Kurt Aeschbacher (Teil 2 von 2)
IBEC Plenary Lecture 1 Dr. Bruce Spiegelman Harvard Medical School May 25, 2022
IBEC Plenary Lecture 1 Dr. Bruce Spiegelman Harvard Medical School May 25, 2022
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma
The promise of novel checkpoint inhibitors for the treatment of HL
The promise of novel checkpoint inhibitors for the treatment of HL
How do you identify HL patients at risk for relapse or disease progression after transplant?
How do you identify HL patients at risk for relapse or disease progression after transplant?
DAS ZELT - David Bröckelmann - Ausschnitte und Interview
DAS ZELT - David Bröckelmann - Ausschnitte und Interview